Skip to main content
Cardiology
FULL MENU
Close Menu
Cardiology
CME
Diseases and Conditions
Acute Coronary Syndromes
Arryhthmias
CAD & Atherosclerosis
Diabetes
Heart Failure
Lipid Disorders
Peripheral Vascular Disorders
Stroke
Hypertension
Thrombosis
Subspecialties
Imaging
Interventional Cardiology & Surgery
Pediatrics
Preventive Care
Multimedia
Podcasts
Videos
Coronavirus Updates
Conference Coverage
SGLT inhibition back on track in phase 3 type T1DM trial
Publish date:
October 18, 2017
AT EASD 2017
cenews@frontlinemedcom.com
Pages
« first
1
2
Next Article:
Vitality predicts T2DM major cardiovascular event risk
Diabetes
Close
MDedge Home
Diseases and Conditions
Acute Coronary Syndromes
Arrhythmias
CAD & Atherosclerosis
COVID-19 Updates
Diabetes
Heart Failure
Lipid Disorders
Long COVID
Peripheral Vascular Disorders
Hypertension
Stroke
Thrombosis
Subspecialties
Imaging
Interventional Cardiology & Surgery
Pediatrics
Preventive Care
Business of Medicine
Medicolegal Issues
Diversity in Medicine
Explore
20th Anniversary
News
Explore
Conference Coverage
From the Journals
Guidelines
Medicine’s Lighter Side
News From the FDA/CDC
News by Conference
Perspectives
Explore
Commentaries
Heart Of The Matter
CME
Conference ReCAP
Supplements
Quizzes and Polls
Explore
MD-IQ
Reader Poll
Multimedia
Explore
Audio
Explore
MDedge Podcasts
Videos
Roundtables
Subscribe to Cardiology News
Medical Directors / Pharmacy Directors
Nurse Practitioners / Physician Assistants
Residents
VA / DoD / PHS
More
MDedge.com